title: Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
abstract: BACKGROUND
  Patients with severe asthma are often inadequately controlled on existing anti-asthma therapy, constituting an unmet clinical need.
  
  
  OBJECTIVE
  This randomized, double-blind, placebo-controlled trial evaluated the ability of omalizumab, a humanized monoclonal anti-IgE antibody, to improve disease control sufficiently to enable inhaled corticosteroid reduction in patients with severe allergic asthma.
  
  
  METHODS
  After a run-in period when an optimized fluticasone dose (> or =1000 microg/day) was received for 4 weeks, patients were randomized to receive subcutaneous omalizumab [minimum 0.016 mg/kg/IgE (IU/mL) per 4 weeks; n=126] or matching placebo (n=120) at intervals of 2 or 4 weeks. The study comprised a 16-week add-on phase of treatment followed by a 16-week fluticasone-reduction phase. Short-/long-acting beta(2)-agonists were allowed as needed.
  
  
  RESULTS
  Median reductions in fluticasone dose were significantly greater with omalizumab than placebo: 60% vs. 50% (P=0.003). Some 73.8% and 50.8% of patients, respectively, achieved a > or =50% dose reduction (P=0.001). Fluticasone dose reduction to < or =500 microg/day occurred in 60.3% of omalizumab recipients vs. 45.8% of placebo-treated patients (P=0.026). Through both phases, omalizumab reduced rescue medication requirements, improved asthma symptoms and asthma-related quality of life compared to placebo.
  
  
  CONCLUSIONS
  Omalizumab treatment improves asthma control in severely allergic asthmatics, reducing inhaled corticosteroid requirements without worsening of symptom control or increase in rescue medication use.
authors.affiliation: RCMB Research Division, Southampton General Hospital, Southampton, UK. sth@soton.ac.uk
authors.forename: S T
authors.initials: ST
authors.lastname: Holgate
authors.forename: A G
authors.initials: AG
authors.lastname: Chuchalin
authors.forename: J
authors.initials: J
authors.lastname: Hébert
authors.forename: J
authors.initials: J
authors.lastname: Lötvall
authors.forename: G B
authors.initials: GB
authors.lastname: Persson
authors.forename: K F
authors.initials: KF
authors.lastname: Chung
authors.forename: J
authors.initials: J
authors.lastname: Bousquet
authors.forename: H A
authors.initials: HA
authors.lastname: Kerstjens
authors.forename: H
authors.initials: H
authors.lastname: Fox
authors.forename: J
authors.initials: J
authors.lastname: Thirlwell
authors.forename: G Della
authors.initials: GD
authors.lastname: Cioppa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage; D002648:Child; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001993:Bronchodilator Agents; C026408:anti-IgE antibodies; D000069444:Omalizumab; D007073:Immunoglobulin E; D000068298:Fluticasone